IPO Year:
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/24/2024 | $12.00 | Buy | Maxim Group |
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
3/A - FibroBiologics, Inc. (0001958777) (Issuer)
3/A - FibroBiologics, Inc. (0001958777) (Issuer)
3/A - FibroBiologics, Inc. (0001958777) (Issuer)
3/A - FibroBiologics, Inc. (0001958777) (Issuer)
3/A - FibroBiologics, Inc. (0001958777) (Issuer)
HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to join the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them b
HOUSTON, March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the appointment of Ruben A. Garcia as General Counsel. He will report to Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer, and be an integral member of the executive leadership team. "The addition of Ruben as our General Counsel rep
HOUSTON, Sept. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2024 Cell & Gene Meeting on the Mesa Conference taking place October 7-9 in Phoenix, Arizona. "We always look forward to attending this very informative and collaborative meeting. For this year's meeting we will present an update of our pre-clinical IND-enabling studies in chronic wound healin
HOUSTON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has engaged with Southern Star Research to provide clinical research organization (CRO) services for FibroBiologics in Australia. Initial CRO services will include preparatory work for a Phase 1/2 clinical trial utilizing product candidate, CYWC628, to treat diabetic foot ulcers. Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics, said,
HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of fibroblast cell-based technology in generating three-dimensional hemopoietic organoids that can give rise to immune cells. The patent details methods of generating three-dimensional organoids capable of giving rise to hematopoietic cells, including precursors, and/or immune cell
HOUSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that Founder and Chief Executive Officer, Pete O'Heeron, will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11 at the Lotte New York Palace Hotel in New York City. FibroBiologics' presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 9, 2024, at 7 a.m.
HOUSTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of fibroblast cell-based technology in an adhesive bandage for wound healing. "Our ongoing exploration of therapeutic applications using fibroblast cells continues to provide unique opportunities for our wound care platform," commented Founder & CEO of FibroBiologics, Pete O'Heeron.
HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, with the U.S. Securities and Exchange Commission. The filing can be viewed through a link on FibroBiologics' website at https://ir.fibrobiologics.com/sec-filings/quarterly-reports. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments
HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present at the JonesTrading Healthcare Seaside Summit occurring July 14-16, 2024, in San Diego, California. Details of the presentations are as follows: Presentation Date: Monday, July 15, 2024Time: 1:45 p.m. PDTWebcast Registration: https://wsw.com/webcast/jones/fblg/1793925 Links to the replay
HOUSTON, June 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the development of a novel artificial thymus organoid that can restore immune function in a severe combined immunodeficiency (SCID) mouse model. The organoid, composed of fibroblasts and thymus derived cells, is capable of generating mature and diverse T cells, including CD4, CD8, and regulatory T cells, in vitro and in vivo. FibroBiologics intends to develop this tech
HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to join the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them b
HOUSTON, June 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present on FibroBiologics' wound care and psoriasis programs at the Extracellular Matrix (ECM) Pharmacology Congress in Copenhagen, Denmark, from June 17-19, 2024. The ECM Pharmacology Congress is a forum to bring leading experts across borders and generations together to discuss how to modulate the ECM in differen
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
Maxim Group initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
- SEC Filing
Company Holds 150+ Patents For Fibroblast-Based Therapeutics And Cures For Chronic Diseases
Gainers Viracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday's pre-market session. The company's market cap stands at $26.7 million. Purple Biotech (NASDAQ:PPBT) stock increased by 14.48% to $0.63. The market value of their outstanding shares is at $16.4 million. Akanda (NASDAQ:AKAN) stock rose 12.54% to $3.05. The market value of their outstanding shares is at $5.8 million. Viridian Therapeutics (NASDAQ:VRDN) shares rose 12.09% to $13.7. The market value of their outstanding shares is at $874.2 million. IGC Pharma (AMEX:IGC) shares increased by 11.21% to $0.48. The company's market cap stands at $36.1 million. OpGen (NASDAQ:OPGN) shares moved upwards by
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Friday. Shares of Vail Resorts, Inc. (NYSE:MTN) fell sharply in today's pre-market trading after the company reported weaker-than-expected results for its third quarter. The company posted quarterly earnings of $9.54 per share, missing market estimates of $10.03 per share. The company’s sales came in at $1.28 billion versus expectations of $1.30 billion, according to data from Benzinga Pro. Vail Resorts shares declined 6.8% to $180.77 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Biomea Fusion, Inc. (NASDAQ:BMEA) shares tu
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 88.8% to $2.02 during Thursday's regular session. The company's market cap stands at $4.7 million. FibroBiologics (NASDAQ:FBLG) shares rose 45.37% to $9.74. The market value of their outstanding shares is at $318.6 million. Aethlon Medical (NASDAQ:AEMD) stock rose 39.58% to $0.61. The company's market cap stands at $3.1 million. American Oncology Network (NASDAQ:AONC) stock rose 32.96% to $3.0. The market value of their outstanding shares is at $30.6 million. Replimune Group (NASDAQ:REPL) shares rose 29.04% to $7.17. The company's market cap stands at $440.6 million. Co-Diagnostics (NASDAQ:CODX) stock rose 27.18% to $1.31. The marke
- SEC Filing
8-K - FibroBiologics, Inc. (0001958777) (Filer)
8-K - FibroBiologics, Inc. (0001958777) (Filer)
8-K - FibroBiologics, Inc. (0001958777) (Filer)
EFFECT - FibroBiologics, Inc. (0001958777) (Filer)
POS AM - FibroBiologics, Inc. (0001958777) (Filer)
10-Q - FibroBiologics, Inc. (0001958777) (Filer)
ARS - FibroBiologics, Inc. (0001958777) (Filer)
DEFA14A - FibroBiologics, Inc. (0001958777) (Filer)
DEF 14A - FibroBiologics, Inc. (0001958777) (Filer)
PRE 14A - FibroBiologics, Inc. (0001958777) (Filer)